
David S. Hong, MD, discusses updated findings from an analysis of 3 trials which ultimately led to the approval of larotrectinib for patients with solid tumors who harbor an NTRK fusion.

David S. Hong, MD, discusses updated findings from an analysis of 3 trials which ultimately led to the approval of larotrectinib for patients with solid tumors who harbor an NTRK fusion.

The addition of eftilagimod alpha to pembrolizumab in patients with PD-1 resistant non–small cell lung cancer led to tumor shrinkage.

Here is a look back at the FDA happenings from March 2023.

According to a phase 1b study, ibrutinib can modulate immune response and lead to some promising immune effects for patients with metastatic pancreatic ductal adenocarcinoma.

Lajos Pusztai, MD, DPhil, discusses the methods and design of the phase 3 KEYNOTE-522 trial.

Amivantamab treatment continued to show tolerability and efficacy in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations whose disease progressed on platinum-based chemotherapy.

Recent successes have been observed for patients with locally advanced, unresectable non–small cell lung cancer regarding new treatment options.

After 3 years of follow-up in the ZUMA-5 trial, patients with relapsed/refractory indolent non-Hodgkin lymphoma treated with axicabtagene ciloleucel had durable responses.

Cary Gross, MD, discusses the findings from a retrospective study which revealed there to be an association between Medicaid insurance, rates of biomarker testing, and patient outcomes among patients with advanced non–small cell lung cancer.

At the 2023 European Lung Cancer Congress, results from the recent findings of the CONTACT-01 trial showed no benefit for patients with metastatic non–small cell lung cancer on the combination of atezolizumab and cabozantinib compared with the standard of care.

Qian Wang, MD, MPH, discusses the changing incidence of small cell lung cancer among patients globally and in the United States.

A phase 1/2 trial investigating GRC 54276 for the treatment of patients with advanced solid tumors and lymphomas will begin following the acceptance of an investigational new drug application for the agent.

Based on findings from a phase 1 trial, osemitamab has gained an orphan drug designation from the FDA for the treatment of patients with pancreatic cancer.

One of the key tools used to detect leukemic cells is measurable residual disease, formerly referred to as minimal residual disease.

Debu Tripathy, MD, discusses the TBCRC049 study which evaluated tucatinib, capecitabine, and trastuzumab in the cerebral spinal fluid of patients with HER2-positive breast cancer and leptomeningeal disease.

Ken Kato, MD, PhD, discusses which patient characteristics to look out for when looking to put a patient on the combination of ipilimumab and nivolumab.

The FDA has granted a fast-track designation for RRx-001 and accepted the investigational new drug application for a phase 2b trial of severe oral mucositis in chemotherapy- and radiation-treated patients with head & neck cancer.

Matthew P. Goetz, MD, discusses the next steps for evaluating treatment with lasofoxifene.

New results from the phase 2 APPLE trial shows how the use of osimertinib in the upfront setting compares with combination therapy in patients with EGFR-positive non–small cell lung cancer.

In an interview with Targeted Oncology, Raajit K. Rampal, MD, PhD, discussed the currently approved JAK inhibitors used to treat patients with myelofibrosis, and exciting movements in the field.

Courtney D. DiNardo, MD, MSCE, provided an overview of venetoclax resistance and interrelated mechanisms, with a spotlight on kinase signaling pathways, TP53 mutation, monocytic, and other forms of resistance.

A full approval has been granted to pembrolizumab by the FDA for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumors.

In an interview, Krisda Chaiyachati, MD, MPH, discussed some of the social determinants of health for patients with cancer and some of the challenges patients undergoing treatment face, including transportation insecurity.

The inaugural participant with AML showing a mutation of FLT3 in a relapsed/refractory form has been recruited into the Phase 1 FRIDA trial.

According to early results from CheckMate 040, nivolumab plus cabozantinib with or without ipilimumab showed good clinical activity and survival.

At the Society of Gynecologic Oncology 2023 Annual Meeting, data showed that with a median follow-up of 25.8 months, the proportion of patients on Arm A of the NRG-GY017 trial of patients with cervical cancer with 2-year disease-free survival rate was 79% vs 59% in Arm B.

As of March 28, 2023, the partial clinical hold on the phase 1/2 VELA trial, which is evaluating the selective CDK2 inhibitor BLU-222 for patients with solid tumors, has been lifted. Blueprint Medicines has resumed the re-initiation of patient enrollment.

Combination therapy with checkpoint blockade, also termed immuno oncology agents, and multikinase tyrosine kinase inhibitors are rapidly becoming the first-line therapy of choice in patients with metastatic clear cell renal cell carcinoma.

PT886, a novel bispecific antibody which targets claudin 18.2 and CD47, is currently being evaluated in a phase 1 study for patients with gastric, gastroesophageal junction and pancreatic adenocarcinomas.

Andrew Kuykendall, MD, discusses recent approvals seen for patients with myeloproliferative neoplasms.